pharmaphorum March 20, 2025
Sanofi says it has reached an agreement with Dren Bio that would see it take control of autoimmune disease treatment DR-0201, a bispecific antibody-based myeloid cell engager with the potential to “reset the immune system.”
Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called Dren-0201, which was set up to develop the therapy. Dren Bio could also make another $1.3 billion tied to future development and launch objectives for DR-0201.
The potentially first-in-class drug, which targets CD20, is able to achieve “deep B-cell depletion” by stimulating cells of the immune system to engulf and destroy B cells in the presence of a specific antigen.
B cells are involved...
Today's Sponsors
Today's Sponsor